Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modulating proinflammatory processes using tocilizumab in major depressive disorder
2017-004624-30Phase 2Completed
- Sponsor
- Linköping University
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tocilizumab in major depressive disorder (MDD), sponsored by Linköping University. Primary endpoint: Change in CNS inflammatory biomarkers. Started Nov 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2017-004624-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004624-30.